Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 2Gynecologic 1

Conditions

Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Endometrial Neoplasms 1

Interventions

Paclitaxel 74pembrolizumab 59Carboplatin 55Bevacizumab 55Specimen Handling 47Magnetic Resonance Spectroscopy 39Cisplatin 34olaparib 28Gemcitabine 26liposomal doxorubicin 24Biopsy 20Taxes 18Topotecan 17Nivolumab 17Doxorubicin 15Cyclophosphamide 15Immunoglobulin G 14Disulfides 14niraparib 12fludarabine 12Letrozole 12lenvatinib 11Surveys and Questionnaires 11atezolizumab 10Drug Therapy 10Brachytherapy 10durvalumab 9Radiotherapy 9Fulvestrant 9Docetaxel 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
TP protocol × Gynecologic × 90 days × Clear all
NCT06532539 2026-04-24

Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma

Shandong Cancer Hospital and Institute

Phase 2 Recruiting
30 enrolled
Gynecologic

Neoplasm Metastasis, Neoplasm Recurrence, Local, Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡